Angioimmunoblastic
T-cell lymphoma is a rare type of peripheral T-cell
lymphoma which is characterized by lymphadenopathy, fever, and arthritis. The
signs and symptoms associated with the disease include pleural effusion,
arthritis, edema, ascites and pruritic skin rash. The neoplastic cells related
to the disease are found in the liver, spleen, lymph nodes and bone marrow.
Angioimmunoblastic T-cell lymphoma can be treated with multiagent
chemotherapy regimen. In addition, steroid is used to get relieve from the
symptoms in reaction to inflammation. The National Cancer Institute is in the process
of developing MEDI-570 as an inducible T-cell co-stimulator protein antagonist
for the treatment of angioimmunoblastic T-cell lymphoma.
Request to Get Free Sample Pages at:
The Lymphoma Academic Research Organisation is also in the process
of developing lenalidomide for the treatment of this medical condition. Some of
the other companies, universities, and organizations having drugs for
angioimmunoblastic T-cell lymphoma in their pipeline includes The Lymphoma
Academic Research Organization, PharmaMar S.A., Innate Pharma S.A. and others.
The report provides a comprehensive understanding of the pipeline
activities covering all drug candidates under various stages of development,
with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product description
and development activities including information about clinical results,
designations, collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment